| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Department of Pulmonary Diseases, University Hospital Dijkzigt, Rotterdam
2 From the Department of Pulmonary Diseases, University Hospital, Groningen, the Netherlands
3 From the Department of Epidemiology and Biostatistics, University Hospital Dijkzigt, Rotterdam
Background: The institution of inhaled corticosteroids is generally advocated for effective treatment of patients with asthma. It is yet unknown what is the best time to start inhaled corticosteroid therapy and especially whether delayed introduction is harmful.
Phase 1: In a previous study in patients with asthma and COPD, we found that 2.5 years of treatment with a β2-agonist plus inhaled corticosteroid (BA+CS) was more effective in improving the FEV1 and the provocative concentration of histamine causing a 20% reduction in FEV1 (PC20) than treatment with a β2-agonist plus anticholinergic (BA+AC) or placebo (BA+PL).
Phase 2: We extended this study with 6 months to investigate whether delayed introduction of inhaled CS therapy (800 µg beclomethasone dipropionate) in the groups previously not treated with inhaled CS (BA±AC) could also improve FEV1 and PC20 to the same degree. A distinction was made between patients with predominantly asthma (high baseline reversibility, 
FEV1 
9% of predicted), and predominantly COPD (low baseline reversibility, FEV1 <9% of predicted).
Results: Improvement of FEV1 percent predicted by inhaled CS was comparable both in the asthmatics between phase 1 (13.8% predicted) and phase 2 (8.5% predicted; p=0.13) as well as in the patients with COPD (2.5% and 1.5% predicted, respectively). PC20, however, increased significantly more in the asthmatics in phase 1 (1.77 doubling concentration [DC]) than in phase 2 (0.79 DC; p=0.03). Improvement of PC20 in the patients with COPD was not significantly higher in phase 1 (0.74 DC) than in phase 2 (0.00 DC; p=0.19).
Conclusions: Our study indicates that although delayed introduction of inhaled CS in asthmatics leads to similar improvements in FEV1, improvements in PC20 are significantly less. These findings in patients with longer-existing asthma concur with other findings in newly detected asthma. We suggest that institution of inhaled CS therapy should not be postponed in asthmatics with documented airways obstruction and reversibility.
Key Words: airway hyperresponsiveness • asthma • COPD • inhaled corticosteroids • lung function
Submitted on October 5, 1995
Accepted on February 14, 1996
This article has been cited by other articles:
|
|
 |
|
  L. Watson, H. A. Kerstjens, K. F Rabe, V. Kiri, G. T Visick, and D. S Postma Obtaining optimal control in mild asthma: theory and practice Fam. Pract., June 1, 2005; 22(3): 305 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Albers, T. Schermer, G. van den Boom, R. Akkermans, C. van Schayck, C. van Herwaarden, and C. van Weel Efficacy of Inhaled Steroids in Undiagnosed Subjects at High Risk for COPD: Results of the Detection, Intervention, and Monitoring of COPD and Asthma Program Chest, December 1, 2004; 126(6): 1815 - 1824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E McKenzie and M. Cruz-Rivera Compatibility of Budesonide Inhalation Suspension with Four Nebulizing Solutions Ann. Pharmacother., June 1, 2004; 38(6): 967 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P A Beckett and P H Howarth Pharmacotherapy and airway remodelling in asthma? Thorax, February 1, 2003; 58(2): 163 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. R. Douma, H. A. M. Kerstjens, A. de Gooijer, S. E. Overbeek, G. H. Koeter, and D. S. Postma Initial Improvements in Lung Function and Bronchial Hyperresponsiveness Are Maintained During 5 Years of Treatment With Inhaled Beclomethasone Dipropionate and Terbutaline Chest, January 1, 2002; 121(1): 151 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. VAN DEN BOOM, M. P. M. H. RUTTEN-VAN MOLKEN, J. MOLEMA, P. R. S. TIRIMANNA, C. VAN WEEL, and C. P. VAN SCHAYCK The Cost Effectiveness of Early Treatment with Fluticasone Propionate 250 {micro}g Twice a Day in Subjects with Obstructive Airway Disease . Results of the DIMCA Program Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2057 - 2066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Lazarus, H. A. Boushey, J. V. Fahy, V. M. Chinchilli, R. F. Lemanske Jr, C. A. Sorkness, M. Kraft, J. E. Fish, S. P. Peters, T. Craig, et al. Long-Acting {beta}2-Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma: A Randomized Controlled Trial JAMA, May 23, 2001; 285(20): 2583 - 2593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. VANACKER, E. PALMANS, J. C. KIPS, and R. A. PAUWELS Fluticasone Inhibits But Does Not Reverse Allergen-Induced Structural Airway Changes Am. J. Respir. Crit. Care Med., March 1, 2001; 163(3): 674 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Childhood Asthma Management Program Research G Long-Term Effects of Budesonide or Nedocromil in Children with Asthma N. Engl. J. Med., October 12, 2000; 343(15): 1054 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. BOUSQUET, P. K. JEFFERY, W. W. BUSSE, M. JOHNSON, and A. M. VIGNOLA Asthma . From Bronchoconstriction to Airways Inflammation and Remodeling Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1720 - 1745. [Full Text]
|
|
|
|
|
|
A. CROCKETT Screening older patients for obstructive airways disease Thorax, June 1, 1999; 54(6): 472 - 473. [Full Text]
|
|
|
|
|
|
G. van den BOOM, C. P. van SCHAYCK, M. P. M. H. RUTTEN-van MOLKEN, P. R. S. TIRIMANNA, J. J. den OTTER, P. M. van GRUNSVEN, M. J. BUITENDIJK, C. L. A. van HERWAARDEN, and C. van WEEL Active Detection of Chronic Obstructive Pulmonary Disease and Asthma in the General Population . Results and Economic Consequences of the DIMCA Program Am. J. Respir. Crit. Care Med., December 1, 1998; 158(6): 1730 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. P. H. VERBERNE, C. FROST, E. J. DUIVERMAN, M. H. GROL, K. F. KERREBIJN, and the Dutch Paediatric Asthma Study Group Addition of Salmeterol versus Doubling the Dose of Beclomethasone in Children with Asthma Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 213 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. BARNES, S. PEDERSEN, and W. W. BUSSE Efficacy and Safety of Inhaled Corticosteroids . New Developments Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): S1 - 53. [Full Text] [PDF]
|
|
|
|
|
|
L. M. FABBRI, G. CARAMORI, B. BEGHÉ, A. PAPI, and A. CIACCIA Physiologic Consequences of Long-term Inflammation Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 195 - 198. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
